Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 9
1966 6
1967 15
1968 30
1969 32
1970 40
1971 36
1972 36
1973 37
1974 41
1975 48
1976 61
1977 40
1978 60
1979 46
1980 51
1981 49
1982 58
1983 57
1984 79
1985 92
1986 90
1987 85
1988 113
1989 113
1990 115
1991 115
1992 114
1993 140
1994 207
1995 203
1996 208
1997 235
1998 242
1999 229
2000 237
2001 224
2002 261
2003 235
2004 321
2005 318
2006 316
2007 301
2008 264
2009 252
2010 275
2011 310
2012 299
2013 313
2014 333
2015 302
2016 257
2017 226
2018 198
2019 188
2020 176
2021 77
Text availability
Article attribute
Article type
Publication date

Search Results

8,050 results
Results by year
Filters applied: . Clear all
Page 1
Hydrocortisone therapy for patients with septic shock.
Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. Sprung CL, et al. N Engl J Med. 2008 Jan 10;358(2):111-24. doi: 10.1056/NEJMoa071366. N Engl J Med. 2008. PMID: 18184957 Free article. Clinical Trial.
At 28 days, 86 of 251 patients in the hydrocortisone group (34.3%) and 78 of 248 patients in the placebo group (31.5%) had died (P=0.51). In the hydrocortisone group, shock was reversed more quickly than in the placebo group. ...
At 28 days, 86 of 251 patients in the hydrocortisone group (34.3%) and 78 of 248 patients in the placebo group (31.5%) had died (P=0. …
Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, Zupan-Simunek V, Coursol A, Beuchée A, Bolot P, Andrini P, Mohamed D, Alberti C; PREMILOC trial study group. Baud O, et al. Lancet. 2016 Apr 30;387(10030):1827-36. doi: 10.1016/S0140-6736(16)00202-6. Epub 2016 Feb 23. Lancet. 2016. PMID: 26916176 Clinical Trial.
In this study, we aimed to assess whether low-dose hydrocortisone improved survival without bronchopulmonary dysplasia in extremely preterm infants. ...FINDINGS: 1072 neonates were screened between May 25, 2008, and Jan 31, 2014, of which 523 were randomly assigned (256 …
In this study, we aimed to assess whether low-dose hydrocortisone improved survival without bronchopulmonary dysplasia in extremely p …
Hydrocortisone Compared with Placebo in Patients with Septic Shock Satisfying the Sepsis-3 Diagnostic Criteria and APROCCHSS Study Inclusion Criteria: A Post Hoc Analysis of the ADRENAL Trial.
Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Glass P, Joyce C, Li Q, McArthur C, Perner A, Rhodes A, Thompson K, Webb S, Myburgh J. Venkatesh B, et al. Anesthesiology. 2019 Dec;131(6):1292-1300. doi: 10.1097/ALN.0000000000002955. Anesthesiology. 2019. PMID: 31651531 Free article. Clinical Trial.
RESULTS: There were 1,950 subjects (973 hydrocortisone and 977 placebo) who met the Sepsis-3 criteria (ADRENAL-Sepsis-3 cohort) and 905 patients (455 hydrocortisone and 450 placebo) who met the APROCCHSS criteria (ADRENAL-APROCCHSS cohort). At 90 days after randomiz …
RESULTS: There were 1,950 subjects (973 hydrocortisone and 977 placebo) who met the Sepsis-3 criteria (ADRENAL-Sepsis-3 cohort) and 9 …
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Bellissant E. Annane D, et al. JAMA. 2002 Aug 21;288(7):862-71. doi: 10.1001/jama.288.7.862. JAMA. 2002. PMID: 12186604 Clinical Trial.
INTERVENTION: Patients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50- micro g tablet once daily) (n = 151) or matching placebos (n = 149) for 7 days. ...CONCLUSION: In our trial, a 7-day treatment wi …
INTERVENTION: Patients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocort …
Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan.
Onland W, Merkus MP, Nuytemans DH, Jansen-van der Weide MC, Holman R, van Kaam AH; SToP-BPD study group. Onland W, et al. Trials. 2018 Mar 9;19(1):178. doi: 10.1186/s13063-018-2505-y. Trials. 2018. PMID: 29523175 Free PMC article. Clinical Trial.
Although the glucocorticoid dexamethasone has been proven to be beneficial for the prevention of BPD, there are concerns about an increased risk of adverse neurodevelopmental outcome. Hydrocortisone has been suggested as an alternative therapy. The aim of the Systemic H
Although the glucocorticoid dexamethasone has been proven to be beneficial for the prevention of BPD, there are concerns about an increased …
The cost-effectiveness of adjunctive corticosteroids for patients with septic shock.
Thompson KJ, Taylor CB, Venkatesh B, Cohen J, Hammond NE, Jan S, Li Q, Myburgh J, Rajbhandari D, Saxena M, Kumar A, Finfer SR; The ADRENAL Management Committee and Investigators and the ANZICS Clinical Trials Group. Thompson KJ, et al. Crit Care Resusc. 2020 Sep;22(3):191-199. Crit Care Resusc. 2020. PMID: 32900325 Clinical Trial.
OBJECTIVE: To determine whether hydrocortisone is a cost-effective treatment for patients with septic shock. ...The incremental cost of hydrocortisone was A$1 254 078 per quality-adjusted life-year gained. ...
OBJECTIVE: To determine whether hydrocortisone is a cost-effective treatment for patients with septic shock. ...The incremental cost …
Residual endogenous corticosteroid production in patients with adrenal insufficiency.
Vulto A, Bergthorsdottir R, van Faassen M, Kema IP, Johannsson G, van Beek AP. Vulto A, et al. Clin Endocrinol (Oxf). 2019 Sep;91(3):383-390. doi: 10.1111/cen.14006. Epub 2019 Jun 20. Clin Endocrinol (Oxf). 2019. PMID: 31059146 Free PMC article. Clinical Trial.
PATIENTS AND MEASUREMENTS: Patients with primary adrenal insufficiency were on stable hydrocortisone and fludrocortisone therapy. Patients with secondary adrenal insufficiency received two different doses of hydrocortisone in a randomized crossover study. Main outco …
PATIENTS AND MEASUREMENTS: Patients with primary adrenal insufficiency were on stable hydrocortisone and fludrocortisone therapy. Pat …
Clinical relevance of tixocortol pivalate-positive patch tests and questionable bioequivalence of different hydrocortisone preparations.
Shaw DW, Maibach HI. Shaw DW, et al. Contact Dermatitis. 2013 Jun;68(6):369-75. doi: 10.1111/cod.12066. Contact Dermatitis. 2013. PMID: 23692037 Clinical Trial.
RESULTS: ROAT was positive in 15 of 20 patients (75%) with hydrocortisone cream versus 6 of 16 (38%) with hydrocortisone ointment (p = 0.02). ...Hydrocortisone creams gave positive patch tests and positive repeated open application tests much more often than …
RESULTS: ROAT was positive in 15 of 20 patients (75%) with hydrocortisone cream versus 6 of 16 (38%) with hydrocortisone ointm …
Preinterventional hydrocortisone sustains the endothelial glycocalyx in cardiac surgery.
Brettner F, Chappell D, Nebelsiek T, Hauer D, Schelling G, Becker BF, Rehm M, Weis F. Brettner F, et al. Clin Hemorheol Microcirc. 2019;71(1):59-70. doi: 10.3233/CH-180384. Clin Hemorheol Microcirc. 2019. PMID: 29843226 Clinical Trial.
One main pathomechanism leading to the edema is the deterioration of the endothelial glycocalyx, a key component of the vascular barrier. In animal models hydrocortisone has proved to be protective for the glycocalyx. OBJECTIVE: This trial evaluates the effect of hydroc
One main pathomechanism leading to the edema is the deterioration of the endothelial glycocalyx, a key component of the vascular barrier. In …
8,050 results